Biogen Inc.
Location
Massachusetts
Founded
1978-02-28
Website
Risk Signals
6605 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Pharmaceutical Preparations, Biological Products, Except Diagnostic Substances, Commercial Physical and Biological Research), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about Biogen Inc.
Live alerts from global media, monitored by Business Radar
2025-02-12 (cnbc.com)
Biogen beats estimates on cost cuts and new drugs like Leqembi, but profit outlook falls short
Biogen expects Leqembi and new rare disease and depression treatments to help offset revenue lost from multiple sclerosis products.
Read more
2024-07-13 (thefinancialanalyst.net)
Biogen Expands in Immunology with Hi-Bio Acquisition, Eyes Leqembi Growth
In the dynamic landscape of biopharmaceuticals, Biogen Inc. (NASDAQ: BIIB) continues to evolve with significant developments in its neurological and…
Read more
2024-03-28 (boursedirect.fr)
Biogen launches its Leqembi in Corée du Sud
Biogen and its Japanese partner Eisai today announced the launch in South Korea of their product against...
Read more
2023-09-15 (reuters.com)
Sandoz dials up product launch plans ahead of market debut
Sandoz plans to launch at least five additional biologic drugs, its CEO Richard Saynor said, as the generics drugs business of Switzerland's Novartis works to enhance its investor appeal ahead of its market debut next month.
Read more
2023-03-17 (mondaq.com)
Biogen Launches BYOOVIZ (Ranibizumab) In Canada - Life Sciences, Biotechnology & Nanotechnology - United States
On March 1, 2023, Biogen Canada Inc. announced that BYOOVIZTM (ranibizumab injection), a biosimilar to Genentech's LUCENTIS, is now available in Canada. BYOOVIZ is an anti-VEGF...
Read more
2023-03-03 (informa.com)
Biogen Launches Lucentis Biosimilar Byooviz In Canada
Biogen has launched the Samsung Bioepis-developed Byooviz version of Lucentis in Canada, marking the first and only ranibizumab biosimilar to be approved and introduced in the market.
Read more
2016-09-07 (pmlive.com)
Biogen launches Remicade biosimilar in the UK
Flixabi provides another low-cost alternative to J&J’s biggest-selling drug
Read more
(jdsupra.com)
Biogen Launches BYOOVIZ (ranibizumab) in Canada
On March 1, 2023, Biogen Canada Inc. announced that BYOOVIZTM (ranibizumab injection), a biosimilar to Genentech’s LUCENTIS, is now available...
Read more